Fadraciclib: a new and improved CDK inhibitor for cancer

Written by Louis Gautier, Future Science Group

A joint effort by the Institute of Cancer Research (ICR; London, UK) and Cyclacel Pharmaceuticals (NJ, USA) has produced a new CDK inhibitor – fadraciclib (previously called CYC065) – that is being trialed in leukemia and select solid malignancies. The recent joint publication in PLOS One describes fadraciclib, its mechanism of action and its therapeutic properties. It is already being tested in early clinical trials targeting select leukemia patients, as well as some solid tumors. The drug is a dual inhibitor of both CDK2 and CDK9, with treated cells undergoing altered gene expression and cell death by apoptosis. Paul Workman,...

To view the full article, please register now for access

It's completely free